592 related articles for article (PubMed ID: 25057888)
1. The molecular regulation of Janus kinase (JAK) activation.
Babon JJ; Lucet IS; Murphy JM; Nicola NA; Varghese LN
Biochem J; 2014 Aug; 462(1):1-13. PubMed ID: 25057888
[TBL] [Abstract][Full Text] [Related]
2. Structure of the pseudokinase-kinase domains from protein kinase TYK2 reveals a mechanism for Janus kinase (JAK) autoinhibition.
Lupardus PJ; Ultsch M; Wallweber H; Bir Kohli P; Johnson AR; Eigenbrot C
Proc Natl Acad Sci U S A; 2014 Jun; 111(22):8025-30. PubMed ID: 24843152
[TBL] [Abstract][Full Text] [Related]
3. Activation of the protein tyrosine phosphatase SHP2 via the interleukin-6 signal transducing receptor protein gp130 requires tyrosine kinase Jak1 and limits acute-phase protein expression.
Schaper F; Gendo C; Eck M; Schmitz J; Grimm C; Anhuf D; Kerr IM; Heinrich PC
Biochem J; 1998 Nov; 335 ( Pt 3)(Pt 3):557-65. PubMed ID: 9794795
[TBL] [Abstract][Full Text] [Related]
4. Distinct Acute Lymphoblastic Leukemia (ALL)-associated Janus Kinase 3 (JAK3) Mutants Exhibit Different Cytokine-Receptor Requirements and JAK Inhibitor Specificities.
Losdyck E; Hornakova T; Springuel L; Degryse S; Gielen O; Cools J; Constantinescu SN; Flex E; Tartaglia M; Renauld JC; Knoops L
J Biol Chem; 2015 Nov; 290(48):29022-34. PubMed ID: 26446793
[TBL] [Abstract][Full Text] [Related]
5. Suppressor of Cytokine Signaling (SOCS) 5 utilises distinct domains for regulation of JAK1 and interaction with the adaptor protein Shc-1.
Linossi EM; Chandrashekaran IR; Kolesnik TB; Murphy JM; Webb AI; Willson TA; Kedzierski L; Bullock AN; Babon JJ; Norton RS; Nicola NA; Nicholson SE
PLoS One; 2013; 8(8):e70536. PubMed ID: 23990909
[TBL] [Abstract][Full Text] [Related]
6. Structural and Functional Characterization of the JH2 Pseudokinase Domain of JAK Family Tyrosine Kinase 2 (TYK2).
Min X; Ungureanu D; Maxwell S; Hammarén H; Thibault S; Hillert EK; Ayres M; Greenfield B; Eksterowicz J; Gabel C; Walker N; Silvennoinen O; Wang Z
J Biol Chem; 2015 Nov; 290(45):27261-27270. PubMed ID: 26359499
[TBL] [Abstract][Full Text] [Related]
7. Regulation of the Jak/STAT signalling pathway.
Finbloom DS; Larner AC
Cell Signal; 1995 Nov; 7(8):739-45. PubMed ID: 8593242
[No Abstract] [Full Text] [Related]
8. Structure of a Janus kinase cytokine receptor complex reveals the basis for dimeric activation.
Glassman CR; Tsutsumi N; Saxton RA; Lupardus PJ; Jude KM; Garcia KC
Science; 2022 Apr; 376(6589):163-169. PubMed ID: 35271300
[TBL] [Abstract][Full Text] [Related]
9. JAK2, the JAK2 V617F mutant and cytokine receptors.
Staerk J; Kallin A; Royer Y; Diaconu CC; Dusa A; Demoulin JB; Vainchenker W; Constantinescu SN
Pathol Biol (Paris); 2007 Mar; 55(2):88-91. PubMed ID: 16904848
[TBL] [Abstract][Full Text] [Related]
10. Tyrosine Kinase 2-mediated Signal Transduction in T Lymphocytes Is Blocked by Pharmacological Stabilization of Its Pseudokinase Domain.
Tokarski JS; Zupa-Fernandez A; Tredup JA; Pike K; Chang C; Xie D; Cheng L; Pedicord D; Muckelbauer J; Johnson SR; Wu S; Edavettal SC; Hong Y; Witmer MR; Elkin LL; Blat Y; Pitts WJ; Weinstein DS; Burke JR
J Biol Chem; 2015 Apr; 290(17):11061-74. PubMed ID: 25762719
[TBL] [Abstract][Full Text] [Related]
11. Janus Kinase 3 (JAK3): A Critical Conserved Node in Immunity Disrupted in Immune Cell Cancer and Immunodeficiency.
Liongue C; Ratnayake T; Basheer F; Ward AC
Int J Mol Sci; 2024 Mar; 25(5):. PubMed ID: 38474223
[TBL] [Abstract][Full Text] [Related]
12. Novel Small Molecule Tyrosine Kinase 2 Pseudokinase Ligands Block Cytokine-Induced TYK2-Mediated Signaling Pathways.
Zhou Y; Li X; Shen R; Wang X; Zhang F; Liu S; Li D; Liu J; Li P; Yan Y; Dong P; Zhang Z; Wu H; Zhuang L; Chowdhury R; Miller M; Issa M; Mao Y; Chen H; Feng J; Li J; Bai C; He F; Tao W
Front Immunol; 2022; 13():884399. PubMed ID: 35693820
[TBL] [Abstract][Full Text] [Related]
13. Protein tyrosine phosphatases in the JAK/STAT pathway.
Xu D; Qu CK
Front Biosci; 2008 May; 13():4925-32. PubMed ID: 18508557
[TBL] [Abstract][Full Text] [Related]
14. Diamino-1,2,4-triazole derivatives are selective inhibitors of TYK2 and JAK1 over JAK2 and JAK3.
Malerich JP; Lam JS; Hart B; Fine RM; Klebansky B; Tanga MJ; D'Andrea A
Bioorg Med Chem Lett; 2010 Dec; 20(24):7454-7. PubMed ID: 21106455
[TBL] [Abstract][Full Text] [Related]
15. Luteolin sensitizes the antiproliferative effect of interferon α/β by activation of Janus kinase/signal transducer and activator of transcription pathway signaling through protein kinase A-mediated inhibition of protein tyrosine phosphatase SHP-2 in cancer cells.
Tai Z; Lin Y; He Y; Huang J; Guo J; Yang L; Zhang G; Wang F
Cell Signal; 2014 Mar; 26(3):619-28. PubMed ID: 24333668
[TBL] [Abstract][Full Text] [Related]
16. JAKs in pathology: role of Janus kinases in hematopoietic malignancies and immunodeficiencies.
Vainchenker W; Dusa A; Constantinescu SN
Semin Cell Dev Biol; 2008 Aug; 19(4):385-93. PubMed ID: 18682296
[TBL] [Abstract][Full Text] [Related]
17. Inhibition of the janus kinase family increases extracellular signal-regulated kinase 1/2 phosphorylation and causes endoreduplication.
Reiterer G; Yen A
Cancer Res; 2006 Sep; 66(18):9083-9. PubMed ID: 16982750
[TBL] [Abstract][Full Text] [Related]
18. ATP binding to the pseudokinase domain of JAK2 is critical for pathogenic activation.
Hammarén HM; Ungureanu D; Grisouard J; Skoda RC; Hubbard SR; Silvennoinen O
Proc Natl Acad Sci U S A; 2015 Apr; 112(15):4642-7. PubMed ID: 25825724
[TBL] [Abstract][Full Text] [Related]
19. Janus kinase 2 activation mechanisms revealed by analysis of suppressing mutations.
Hammarén HM; Virtanen AT; Abraham BG; Peussa H; Hubbard SR; Silvennoinen O
J Allergy Clin Immunol; 2019 Apr; 143(4):1549-1559.e6. PubMed ID: 30092288
[TBL] [Abstract][Full Text] [Related]
20. Dual signaling role of the protein tyrosine phosphatase SHP-2 in regulating expression of acute-phase plasma proteins by interleukin-6 cytokine receptors in hepatic cells.
Kim H; Baumann H
Mol Cell Biol; 1999 Aug; 19(8):5326-38. PubMed ID: 10409724
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
